Understanding Ozempic Gastroparesis: What Evidence Do You Need?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Science to Targeted Risk Assessment

If you've been taking Ozempic and now struggle with persistent nausea, vomiting, or abdominal pain, you may be wondering if the medication caused gastroparesis. The medical community has long recognized that certain drugs can slow gastric emptying, and this concern has led to focused research on GLP-1 receptor agonists. This page explains what evidence can show a link between Ozempic and gastroparesis, especially for those in Florida.

The Medical Evidence: Ozempic and Gastroparesis

The association between Ozempic (semaglutide) and gastroparesis has become a significant medical and legal concern, particularly for patients in Florida who may have developed this condition after using the medication. Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of a mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, where a radiolabeled meal is tracked to assess the rate of stomach emptying. The clinical presentation can be debilitating, often requiring dietary modifications, prokinetic medications, and, in severe cases, interventions like gastric electrical stimulation. Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes. Its pharmacology involves slowing gastric emptying as a mechanism to reduce postprandial glucose spikes. However, this effect can become pathological in some patients, leading to gastroparesis. Clinical trial data from the FDA label indicate that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 32.7% for Ozempic 0.5 mg and 36.4% for Ozempic 1 mg, compared to 15.3% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (1.9% for placebo, 3.5% for 0.5 mg, 2.7% for 1 mg), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data underscore the drug's impact on gastrointestinal motility.

Mechanistic Pathway and Warning Adequacy

The mechanistic pathway linking Ozempic to gastroparesis involves its action on GLP-1 receptors in the gut, which slows gastric emptying. While this is intended to improve glycemic control, prolonged or excessive slowing can lead to gastroparesis, especially in susceptible individuals. The FDA label does not explicitly list gastroparesis as a warning, but the high incidence of gastrointestinal adverse reactions suggests a potential for this condition. The adequacy of warnings regarding Ozempic and gastroparesis is a central issue in legal claims. The label includes a warning for hypersensitivity reactions, such as anaphylaxis and angioedema, but does not specifically address gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This gap may be considered insufficient by affected patients, as the drug's mechanism directly implicates gastric motility.

Statute of Limitations for Ozempic Claims in Florida

For patients in Florida considering a settlement related to Ozempic-induced gastroparesis, the statute of limitations is a critical factor. In Florida, the statute of limitations for personal injury claims is generally four years from the date the injury was discovered or should have been discovered with reasonable diligence. For product liability claims, including failure to warn, the timeframe may be similar, but it is essential to consult with a legal professional to determine the specific deadline based on individual circumstances. The timeline between exposure to Ozempic and documented harm is also important. Gastroparesis symptoms may develop weeks to months after starting the medication, and diagnosis often requires specialized testing. Patients should document the start date of Ozempic use, the onset of symptoms, and the date of diagnosis to establish a clear timeline.

Settlement Considerations and Evidence Strength

Settlement-related considerations for affected patients include the strength of evidence linking Ozempic to gastroparesis, the severity of the condition, and the impact on quality of life. The clinical trial data showing a higher incidence of gastrointestinal adverse reactions in Ozempic users compared to placebo provides a foundation for claims. However, individual cases may vary based on factors such as pre-existing gastrointestinal conditions, concurrent medications, and duration of use. Patients should also consider the potential for future medical expenses, lost wages, and pain and suffering when evaluating settlement offers. In summary, the evidence from clinical trials indicates a clear association between Ozempic and gastrointestinal adverse reactions, including those that could lead to gastroparesis. The adequacy of warnings is questionable, as the label does not specifically address this risk. Florida patients must be aware of the statute of limitations and the importance of documenting the timeline of exposure and harm. Legal and medical consultation is recommended to navigate the complexities of a potential settlement. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166)

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Florida?

In Florida, the statute of limitations for personal injury claims, including product liability, is generally four years from the date the injury was discovered or should have been discovered. For Ozempic-induced gastroparesis, this means you must file a claim within four years of when you knew or reasonably should have known that your gastroparesis was caused by Ozempic. It is crucial to consult with an attorney to determine your specific deadline.

Does the FDA label for Ozempic warn about gastroparesis?

The FDA label for Ozempic does not explicitly list gastroparesis as a warning. It does include warnings for hypersensitivity reactions and notes a high incidence of gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not specifically address the risk of gastroparesis, which may be considered a gap in warnings by affected patients.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.